{
  "id": 11361672,
  "title": "Pan-Coronavirus Protease Engagement and Differentiated Pharmacology of Antiviral Candidate CMX990",
  "url": "https://urgent.news/2026/10/01/pan-coronavirus-protease-engagement-and-differentiated-pharmacology",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.09.29.755428v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "COVID-19 highlighted the need for antivirals that can be rapidly deployed against both current and future coronavirus threats. CMX990 is a clinical stage coronavirus main protease (Mpro) inhibitor bearing a unique trifluoromethoxymethyl ketone warhead. Here, we broadly evaluate its pan-coronavirus target engagement, antiviral breadth, and pharmacologic differentiation. Across a reporter panel of…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}